David Dardashti, a leading expert in ibogaine treatment, has announced plans to expand research on the most effective ibogaine treatment protocols. This expansion is aimed at increasing the company’s profit contributions to 30 percent, with the goal of obtaining $500,000 per year for research purposes.
Ibogaine, a psychoactive substance found in the root bark of the African shrub Tabernanthe iboga, has been shown to have potential in treating addiction and other mental health disorders. David Dardashti’s company has been at the forefront of ibogaine treatment, constantly improving protocols and conducting research to enhance its effectiveness.
The company’s expansion plans include investing in state-of-the-art research facilities and hiring top researchers in the field of ibogaine treatment. This will allow for more in-depth studies and clinical trials, ultimately leading to a better understanding of ibogaine’s potential and its impact on patients.
David Dardashti believes that this expansion will not only benefit the company but also the patients seeking ibogaine treatment. By increasing the company’s profit contributions to 30 percent, more resources can be allocated towards research, leading to more effective treatment options for those struggling with addiction and other mental health disorders.
The company’s commitment to advancing ibogaine treatment is evident in its efforts to increase research funding. With this expansion, David Dardashti and his team hope to make significant strides in the field of ibogaine treatment and provide hope for those in need.